Again, IL-1α release was not altered when Poly dA:dT was co-administered with Indo to both exacerbated (Figure 3C) and stable (Figure 3D) COPD-derived PBMCs, implying that the treatment with classical anti-inflammatory agents does not modify the AIM2 inflammasome-dependent inflammatory pathway in COPD patients. The gene discussed is IL1A; the disease is chronic obstructive pulmonary disease.